<DOC>
	<DOCNO>NCT00360035</DOCNO>
	<brief_summary>Defects apoptotic process lead onset cancer allow cell grow unchecked oncogenic signal present . Obatoclax design restore apoptosis inhibition Bcl-2 family protein , thereby reinstate natural process cell death often inhibited cancer cell .</brief_summary>
	<brief_title>Safety Efficacy Obatoclax Mesylate ( GX15-070MS ) Treatment Myelofibrosis With Myeloid Metaplasia</brief_title>
	<detailed_description>This multi-center , open-label , Phase II study single-agent obatoclax administer 2-week cycle 24-hour infusion every 2 week fix dose 60 mg patient myelofibrosis . Infusions may administer outpatient basis . No investigational commercial agent therapy describe protocol may administer intent treat patient 's malignancy . Supportive care measure include direct control symptom result myelofibrosis ( blood product , growth factor , hydroxyurea , etc . ) allow .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<criteria>Histologically confirm myelofibrosis myeloid metaplasia . No limitation allowable type amount prior therapy . Patients must normal organ function . Must willing submit blood sampling plan PK PD analyze . Must ability understand willingness sign write informed consent form . No agent therapy administer intent treat malignancy . Patients prior exposure obatoclax . Uncontrolled , intercurrent illness . Pregnant woman woman breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>